Anandamide (AEA) Cannabinoid Research

Anandamide (AEA) Research Dashboard

123

Primary Studies

123

Related Studies

246

Total Studies

Clinical Studies

2

Double-blind human trials

10

Clinical human trials

Pre-Clinical Studies

29

Meta-analyses/Reviews

50

Animal studies

31

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 246 studies associated with Anandamide (AEA).

Here is a small sampling of Anandamide (AEA) studies by title:


Components of the Anandamide (AEA) Research Dashboard

  • Top medical conditions associated with Anandamide (AEA)
  • Proven effects in clinical trials for Anandamide (AEA)
  • Receptors associated with Anandamide (AEA)
  • Individual study details for Anandamide (AEA)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Anandamide (AEA)

Description of Anandamide (AEA)

Anandamide was the first endogenous (naturally occurring inside the human body) cannabinoid to be discovered by Raphael Mechoulam in 1995. Mechoulam and his team named the compound combining the Sanskrit word for bliss, "ananda," and the word "amide" describing an organic chemical compound to arrive at the name anandamide. The naturally occurring enzyme fatty acid amide hydrolase (FAAH) breaks down AEA.

Other Names:

Anandamide (N-arachidonyl ethanolamide)

Anandamide (AEA) Properties and Effects

Anti-inflammatory via PPAR-Gamma, TRPV1 induced vasodilation

Anandamide (AEA) Receptor Binding

Weak affinity for CB1 with a mean Ki 239.2nM. Weak affinity for CB2 with a mean Ki 439.5nM. Binds with TRPV1. Binds with PPARy with an EC50 of 8 μM.

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.